Nikhil Prasad Fact checked by:Thailand Medical News Team Nov 20, 2024 2 hours, 35 minutes ago
Medical News: Researchers from the Icahn School of Medicine at Mount Sinai-USA and various prestigious institutions worldwide have unveiled compelling findings about the role of extracellular vesicles (EVs) in severe COVID-19 cases. These tiny, naturally occurring particles, which transport proteins and other molecules between cells, may be critical players in the progression of COVID-19.
COVID-19 Study Links Extracellular Vesicles to Severe Outcomes
The study examined 39 hospitalized patients with severe symptoms, 29 of whom were treated with the anti-inflammatory drug tocilizumab. The findings could reshape how we predict and manage severe COVID-19 cases.
This
Medical News report dives into their groundbreaking work and how these vesicles - laden with viral proteins - might serve as key biomarkers for predicting outcomes and complications, including long COVID.
Extracellular Vesicles and Viral Proteins
Extracellular vesicles are minute particles that act like cellular messengers, ferrying materials from one cell to another. The study revealed that in patients with severe COVID-19, these vesicles often carried SARS-CoV-2 spike (S) and nucleocapsid (N) proteins. By analyzing blood samples taken at various intervals during hospitalization, researchers discovered that the levels of these viral proteins in EVs directly correlated with worse respiratory function, elevated blood pressure, and multi-organ dysfunction.
The researchers also identified a connection between high EV spike protein levels and a weakened antibody response. This means that individuals whose vesicles carried more viral proteins might struggle to mount an effective immune response, leaving them more vulnerable to severe disease outcomes.
Tocilizumab’s Mixed Role
Tocilizumab, a drug commonly used to dampen inflammation, appeared to lower the levels of viral proteins in extracellular vesicles. Patients who received two doses of tocilizumab saw a more significant decrease in these proteins, suggesting the drug's potential to mitigate some of COVID-19’s damaging effects. However, tocilizumab did not universally improve survival rates, highlighting its limitations in addressing the broader complications of severe COVID-19.
Key Findings of the Study
The study’s main takeaways include the following:
-EV Viral Protein Levels and Severity: Patients with higher EV spike protein levels were more likely to experience severe symptoms, including poor respiratory function, increased blood pressure, and reduced overall survival.
-Immune Response Challenges: An increase in EV spike protein levels coincided with reduced levels of anti-SARS-CoV-2 antibodies, indicating an impaired immune response.
-Tocilizumab’s Impact: This drug reduced the levels of viral proteins in EVs, particularly in pati
ents who received two doses. However, it did not significantly alter survival outcomes.
-Correlations with Organ Function: The dynamic levels of EV spike proteins also correlated with markers of coagulation and inflammation, such as fibrinogen, and with impaired lung function and elevated blood pressure.
The Role of Extracellular Vesicles in Long COVID
As COVID-19 continues to affect millions, understanding the potential long-term effects of the virus remains critical. Researchers speculate that extracellular vesicles could play a role in the development of long COVID symptoms, including chronic fatigue, respiratory issues, and cardiovascular complications. The persistence of viral proteins in EVs for weeks after infection suggests that these particles may contribute to ongoing inflammation and organ damage.
The study opens the door for future research into how EVs might be used to predict or even prevent long COVID. By tracking the levels and types of proteins carried by these vesicles, doctors could potentially identify at-risk patients and intervene earlier.
A New Frontier in COVID-19 Biomarkers
The implications of this research are far-reaching. Extracellular vesicles could serve as a minimally invasive way to monitor disease progression and predict outcomes. Unlike traditional methods, which rely on blood tests or imaging, analyzing EVs could provide a more comprehensive picture of how the virus interacts with the body’s immune system and organs.
The findings also suggest that therapies targeting Extracellular Vesicles or the proteins they carry could offer new avenues for treatment. By disrupting the ability of EVs to transport viral proteins, scientists might be able to mitigate some of the severe complications associated with COVID-19.
Conclusion
This study highlights the significant role of extracellular vesicles in the progression of severe COVID-19. By carrying viral proteins, these vesicles contribute to immune suppression, multi-organ dysfunction, and worse patient outcomes. While tocilizumab shows promise in reducing EV viral protein levels, its impact on survival rates remains limited. Importantly, the research underscores the potential of Extracellular Vesicles (EVs) as biomarkers for predicting disease severity and the development of long COVID.
As we navigate the ongoing challenges of the pandemic, these findings provide hope for better diagnostic tools and treatments. Future studies will be essential to validate these results and explore the full potential of EVs in combating COVID-19 and its long-term effects.
The study findings were published in the peer-reviewed Journal of Extracellular Vesicles.
https://isevjournals.onlinelibrary.wiley.com/doi/10.1002/jev2.70001
For the latest COVID-19 News, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/news/study-reveals-role-of-extracellular-vesicles-in-covid-19
https://www.thailandmedical.news/news/role-of-extracellular-vesicles-in-covid-19-inflammation
https://www.thailandmedical.news/news/extracellular-histones-and-procoagulant-extracellular-vesicles-drive-the-prothrombotic-state-in-covid-19
https://www.thailandmedical.news/news/french-researchers-uncover-that-annexin-v-positive-extracellular-vesicles-could-be-promising-biomarkers-of-severe-covid-19-disease
Share
Tweet
Share
